Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer : the initial clinical experience

Ishida, Naoko; Araki, Kazuhiro; Sakai, Takehiko; Kobayashi, Kokoro; Kobayashi, Takayuki; Fukada, Ippei; Hosoda, Mitsuchika; Yamamoto, Mitsugu; Ichinokawa, Kazuomi; Takahashi, Shunji; Iwase, Takuji; Ito, Yoshinori; Yamashita, Hiroko

Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer : the initial clinical experience

Ishida, Naoko; Araki, Kazuhiro; Sakai, Takehiko et al.

Breast cancer, 2016, 23(4), 617-623

Permalink : https://hdl.handle.net/2115/66413

このアイテムのアクセス数:985件（2026-08-16 10:10 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
BreastCancer23_617	pdf	401 KB	770

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/66413
タイトル	Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer : the initial clinical experience
著者	Ishida, Naoko ; Araki, Kazuhiro ; Sakai, Takehiko ; Kobayashi, Kokoro ; Kobayashi, Takayuki ; Fukada, Ippei ; Hosoda, Mitsuchika ; Yamamoto, Mitsugu ; Ichinokawa, Kazuomi ; Takahashi, Shunji ; Iwase, Takuji ; Ito, Yoshinori ; Yamashita, Hiroko
著者名 Ishida, Naoko
著者名 Araki, Kazuhiro
著者名 Sakai, Takehiko
著者名 Kobayashi, Kokoro
著者名 Kobayashi, Takayuki
著者名 Fukada, Ippei
e-Rad_Researcher 40443931 著者名 Hosoda, Mitsuchika
著者名 Yamamoto, Mitsugu
著者名 Ichinokawa, Kazuomi
e-Rad_Researcher 90221358 著者名 Takahashi, Shunji
著者名 Iwase, Takuji
e-Rad_Researcher 00261131 著者名 Ito, Yoshinori
e-Rad_Researcher 70332947 著者名 Yamashita, Hiroko
言語	英語
キーワード	Fulvestrant
	Metastatic breast cancer
	Advanced breast cancer
	Postmenopausal
	Endocrine therapy
発行日	2016-07
出版者	Springer
収録物名	Breast cancer
巻(号)	23(4)
ページ	617-623
抄録	Background: Fulvestrant 500 mg is currently approved for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer after failure of prior endocrine therapies. Methods: A total of 117 postmenopausal women with metastatic breast cancer, who experienced progression after previous endocrine therapies, were treated with fulvestrant 500 mg between January 2012 and June 2014. Clinical response, time to progression (TTP) and adverse events were investigated. Results: Ninety-nine patients had recurrent breast cancer and 18 patients had stage IV disease. Patients had received a median of two endocrine therapies and a median of two chemotherapies, prior to fulvestrant. There were 10 patients with partial response, 39 patients with long stable disease, 18 patients with stable disease, and 50 patients with progressive disease, so that the objective response rate was 8.5 %, with a clinical benefit rate of 41.9 %. The median TTP was 6.1 months. The absence of liver metastases, a small number of previous chemotherapies, and the longer duration of first-line endocrine therapy were positively correlated with TTP in univariate analysis. In multivariate analysis, a significant association was observed between TTP and duration of first-line endocrine therapy. Serious adverse events were observed in one patient with pulmonary embolism and in one patient with psychiatric symptoms. Conclusions: Fulvestrant 500 mg is an effective and well-tolerated treatment for postmenopausal women with metastatic breast cancer that had progressed after prior endocrine therapies. Patients with acquired resistance to endocrine therapies might be good candidates for fulvestrant therapy regardless of the number of prior endocrine treatments.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	The final publication is available at link.springer.com
PISSN	1340-6868
関連情報	PMID 25896598
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s12282-015-0612-0